# The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

> **NCT01507480** · PHASE1 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 42 (actual)

## Conditions studied

- Rendu Osler Disease
- Telangiectasia, Hereditary Hemorrhagic

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01507480
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01507480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01507480, "The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01507480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*